Want to see FBLG full AI Analyst Report?
FBLG Stock Chart & Stats
$0.71
-$0.08(-11.92%)
At close: 4:00 PM EDT
$0.71
-$0.08(-11.92%)
Day’s Range― - ―
52-Week Range$0.62 - $12.81
Previous Close$0.67
Volume161.72K
Average Volume (3M)978.93K
Market Cap
$8.59M
Enterprise Value$3.89
Total Cash (Recent Filing)$3.52M
Total Debt (Recent Filing)$1.46M
Price to Earnings (P/E)―
Beta0.89
Next Earnings
Nov 17, 2026EPS Estimate
-0.63Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-5.57
Shares Outstanding6,658,193
10 Day Avg. Volume1,423,641
30 Day Avg. Volume978,931
Financial Highlights & Ratios
PEG Ratio-0.02
Price to Book (P/B)1.63
Price to Sales (P/S)0.00
P/FCF Ratio-0.60
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$6.00Price Target Upside745.07% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-4.01
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Improved Balance Sheet LeverageLower debt and positive equity provide a stronger capitalization base than in 2024, reducing leverage-related pressure. This improves financial flexibility as the company funds clinical and research activities, although ongoing losses still weaken the balance sheet.
Enhanced Scientific LeadershipAdding a director with deep genomics, molecular biology and biomedical research expertise could strengthen oversight of the fibroblast-based pipeline. Her background may support better research strategy and translation of therapies toward chronic-disease applications.
Recent Capital AccessThe financing supplies near-term working capital for research and corporate operations and preserves access to additional warrant proceeds. This supports execution of the pipeline, though the security structure may increase dilution and does not remove funding needs.
Bears Say
Nasdaq Delisting RiskThe delisting determination creates a significant structural financing and market-access risk. Losing Nasdaq eligibility could reduce investor access, complicate future capital raises and weaken the company’s ability to fund development, even with an appeal pending.
No Revenue And Persistent LossesA pre-commercial model leaves FibroBiologics without operating revenue to offset research costs. Sustained, sizable losses indicate that profitability depends on successful development, regulatory progress and eventual commercialization rather than current business operations.
Sustained Cash BurnPersistent negative operating and free cash flow means the company consumes cash while it develops its therapies. Continued reliance on external funding increases dilution and refinancing risk and could constrain research progress if capital markets become less accessible.
FibroBiologics, Inc. News
FBLG FAQ
What was FibroBiologics, Inc.’s price range in the past 12 months?
FibroBiologics, Inc. lowest stock price was $0.62 and its highest was $12.81 in the past 12 months.
What is FibroBiologics, Inc.’s market cap?
FibroBiologics, Inc.’s market cap is $8.59M.
When is FibroBiologics, Inc.’s upcoming earnings report date?
FibroBiologics, Inc.’s upcoming earnings report date is Nov 17, 2026 which is in 87 days.
How were FibroBiologics, Inc.’s earnings last quarter?
FibroBiologics, Inc. released its earnings results on Jul 31, 2026. The company reported -$0.66 earnings per share for the quarter, beating the consensus estimate of -$0.93 by $0.27.
Is FibroBiologics, Inc. overvalued?
According to Wall Street analysts FibroBiologics, Inc.’s price is currently Undervalued.
Does FibroBiologics, Inc. pay dividends?
FibroBiologics, Inc. does not currently pay dividends.
What is FibroBiologics, Inc.’s EPS estimate?
FibroBiologics, Inc.’s EPS estimate is -0.63.
How many shares outstanding does FibroBiologics, Inc. have?
FibroBiologics, Inc. has 6,658,193 shares outstanding.
What happened to FibroBiologics, Inc.’s price movement after its last earnings report?
FibroBiologics, Inc. reported an EPS of -$0.66 in its last earnings report, beating expectations of -$0.93. Following the earnings report the stock price went up 12.857%.
Which hedge fund is a major shareholder of FibroBiologics, Inc.?
Currently, no hedge funds are holding shares in FBLG
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
FibroBiologics, Inc.
FibroBiologics, Inc. operates as a clinical-stage biopharmaceutical firm, advancing therapies derived from fibroblasts toward commercialization within the United States. The company's pipeline includes CybroCell, currently being developed to address degenerative disc disease; CYMS101, targeting multiple sclerosis; and CYWC628 for wound repair. Further demonstrating its broad scope, early-stage investigations are underway for CYTER915, aimed at restoring or enhancing thymus and/or spleen function; CYPS317, for psoriasis; and TCB190, designed to combat specific cancers. FibroBiologics was founded in 2021 and is situated in Houston, Texas.
FBLG Stock 12 Month Forecast
Average Price Target
$6.00
▲(745.07% Upside)
Technical Analysis
Bioline RX Ltd Sponsored ADR
―
Curis
―
Synlogic
―
Lexaria Bioscience
―
Processa Pharmaceuticals
―
Ownership Overview
94.16% Insiders
1.04% Mutual Funds
2.42% Other Institutional Investors
1.96% Public Companies and
Individual Investors